Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT01002547

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01002547
Other papers using this trial's data
  • Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial Diabetes care, 2019-08 DOI, PubMed 31332029

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01002547. Randomized; triple masking; primary purpose treatment. Start 2010-06-24 (actual); primary completion 2016-09-30 (actual). Results posted on 2018-09-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Acronym
VA NASH
Condition
Nonalcoholic Steatohepatitis
Intervention (Drug)
pioglitazone-placebo
Intervention (Drug)
pioglitazone
Intervention (Dietary supplement)
Vitamin E
Intervention (Drug)
pioglitazone-placebo
Intervention (Dietary supplement)
Vitamin E
Intervention (Drug)
Vitamin E-placebo
Lead sponsor
VA Office of Research and Development (class: US federal agency)

Record details

Record id
cardio:ct-nct01002547
Content hash
04040ec2839846033751490be5adc336cf0c937ed7b05e4f5a9741173fcb18fb